Genotropin GoQuick 12mg Pfizer 1 vial [1x36IU]

Genotropin GoQuick 12mg Pfizer 1 vial [1x36IU]

$496.51

  • EUR: € 449.49

SKU: 24-7.is5945_ Category:
pfizer

Brand

Pfizer

Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC). Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. This approval follows the medicine’s approval by the U.S. Food and Drug Administration (FDA) in October 2018.
pfizer

Customers' review

5 stars 0 0 %
4 stars 0 0 %
3 stars 0 0 %
2 stars 0 0 %
1 star 0 0 %

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may write a review.